We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two unique drug discovery approaches. The first approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses. Our most advanced ImmunoPhage™️ program, SNS-301, is currently enrolling patients in a Phase 1/2 clinical trial, as a potential treatment for squamous cell carcinoma of the head and neck (SCCHN). An additional ImmunoPhage™️ program includes SNS-401, an ImmunoPhage™️ cocktail for the treatment of Merkel Cell Carcinoma. We plan to submit an investigation new drug submission in the first half of 2022 for this product candidate. The second approach is our monoclonal antibody (mAb) and nanobody platform, which are comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. SNS-VISTA is our most advanced antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). IND-enabling studies for SNS-VISTA are expected by the end of 2021. Through the targeted use of these programs, we believe we can further enhance therapeutic activity.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30Read More

  • Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Dose-dependent, ASPH-specific immune responses observed Company to initiate SNS-301 Phase 2 study in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

    SNS-301 demonstrated a favorable safety profile, improvements in disease parameters, and robust antigen-specific immune responses Clinical results presented in Poster Discussion session at ESMO 2018 Company to initiate Phase 2 study of SNS-301 in multiple solid tumor indications and hematologicalRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30Read More

  • Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Dose-dependent, ASPH-specific immune responses observed Company to initiate SNS-301 Phase 2 study in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

    SNS-301 demonstrated a favorable safety profile, improvements in disease parameters, and robust antigen-specific immune responses Clinical results presented in Poster Discussion session at ESMO 2018 Company to initiate Phase 2 study of SNS-301 in multiple solid tumor indications and hematologicalRead More

Signup For Update

sign up for newsletter and get the latest update